LUUKKAA M[au] - Search Results

Year	Number of Results
2002	1
2003	2
2006	3
2007	2
2009	2
2012	1
2013	1
2020	1
2022	1
2023	2
2026	0

1

Hypopharyngeal carcinoma in Finland from 2005 to 2014: outcome remains poor after major changes in treatment.

Keski-Säntti H, Luukkaa M, Carpén T, Jouppila-Mättö A, Lehtiö K, Mäenpää H, Vuolukka K, Vahlberg T, Mäkitie A. Keski-Säntti H, et al. Among authors: luukkaa m. Eur Arch Otorhinolaryngol. 2023 Mar;280(3):1361-1367. doi: 10.1007/s00405-022-07648-5. Epub 2022 Sep 12. Eur Arch Otorhinolaryngol. 2023. PMID: 36094562 Free PMC article.

2

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, Luukkaa M, Nyandoto P, Hemminki A, Nilsson S, McCaffrey J, Asola R, Turpeenniemi-Hujanen T, Laestadius F, Tasmuth T, Sandberg K, Keane M, Lehtinen I, Luukkaala T, Joensuu H; PROSTY study group. Kellokumpu-Lehtinen PL, et al. Among authors: luukkaa m. Lancet Oncol. 2013 Feb;14(2):117-24. doi: 10.1016/S1470-2045(12)70537-5. Epub 2013 Jan 4. Lancet Oncol. 2013. PMID: 23294853 Clinical Trial.

3

Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).

Josefsson A, Jellvert Å, Holmberg E, Brasso K, Meidahl Petersen P, Aaltomaa S, Luukkaa M, Verhagen P, de Wit R, Ahlgren G, Andrén O, Castellanos E, Seke M, Widmark A, Damber JE; SPCG14-investigators. Josefsson A, et al. Among authors: luukkaa m. Acta Oncol. 2023 Apr;62(4):372-380. doi: 10.1080/0284186X.2023.2199940. Epub 2023 Apr 19. Acta Oncol. 2023. PMID: 37073813 Free article. Clinical Trial.

4

Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.

Kellokumpu-Lehtinen PL, Marttila T, Jekunen A, Hervonen P, Klintrup K, Kataja V, Utriainen T, Luukkaa M, Leskinen M, Pulkkanen K, Kautio AL, Huttunen T. Kellokumpu-Lehtinen PL, et al. Among authors: luukkaa m. Anticancer Res. 2020 Dec;40(12):6915-6921. doi: 10.21873/anticanres.14715. Epub 2020 Dec 7. Anticancer Res. 2020. PMID: 33288585 Clinical Trial.

5

Oral tongue carcinoma and its treatment in Finland.

Mäkitie AA, Koivunen P, Keski-Säntti H, Törnwall J, Pukkila M, Laranne J, Luukkaa M, Vuola J, Joensuu T, Kajanti M, Grénman R. Mäkitie AA, et al. Among authors: luukkaa m. Eur Arch Otorhinolaryngol. 2007 Mar;264(3):263-7. doi: 10.1007/s00405-006-0158-z. Epub 2006 Sep 21. Eur Arch Otorhinolaryngol. 2007. PMID: 17021781

6

Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor.

Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S. Peltola K, et al. Among authors: luukkaa m. Neoplasia. 2009 Jul;11(7):629-36. doi: 10.1593/neo.81038. Neoplasia. 2009. PMID: 19568408 Free PMC article.

7

Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.

Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, Grénman R. Luukkaa M, et al. Head Neck. 2006 Mar;28(3):225-34. doi: 10.1002/hed.20322. Head Neck. 2006. PMID: 16302191

8

Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.

Hervonen P, Joensuu H, Joensuu T, Ginman C, McDermott R, Harmenberg U, Nyandoto P, Luukkaala T, Hemminki A, Zaitsev I, Heikkinen M, Nilsson S, Luukkaa M, Lehtinen I, Kellokumpu-Lehtinen PL. Hervonen P, et al. Among authors: luukkaa m. Anticancer Res. 2012 Mar;32(3):953-6. Anticancer Res. 2012. PMID: 22399616 Clinical Trial.

9

Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival.

Rautava J, Luukkaa M, Heikinheimo K, Alin J, Grenman R, Happonen RP. Rautava J, et al. Among authors: luukkaa m. Oral Oncol. 2007 Oct;43(9):911-9. doi: 10.1016/j.oraloncology.2006.11.012. Epub 2007 Jan 25. Oral Oncol. 2007. PMID: 17257885

10

Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.

Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H, Kronqvist P, Jaakkola PM. Jokilehto T, et al. Among authors: luukkaa m. Clin Cancer Res. 2006 Feb 15;12(4):1080-7. doi: 10.1158/1078-0432.CCR-05-2022. Clin Cancer Res. 2006. PMID: 16489060

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year